Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020.
Mitchell L WatersPaul I DarganChristopher YatesAlison M DinesFlorian EyerIsabelle GiraudonFridtjof HeyerdahlKnut Erik HovdaMatthias E LiechtiÒscar MiróOdd Martin VallersnesKurt AnseeuwRobertas BadarasMarcin BitelJeffrey BonniciMiran BrvarBlazena CaganovaFeriyde CalýskanAlessandro CeschiKaram ChamounLaurence DavelooseMiguel GaliciaBirgit GartnerKetevan GoroziaDamjan GrencFemke M J GresnigtLaura HondebrinkGesche JürgensJutta KonstariSoso KutubidzeGabija LaubnerEvangelia LiakoniViesturs LigutsCathelijne LyphoutRoy McKennaBruno MégarbaneAdrian MoughtyGabriela Viorela NitescuRoberta NosedaNiall O'ConnorRaido PaasmaJuan Ortega PerezMarius PerminasPer Sverre PersettKristiina PõldErik PuchonJordi PuiguriguerJulia Radenkova-SaevaJan RulisekCaroline SamerYasmin SchmidIrene ScholzRoberts StašinskisJonas SurkusIrma Van den Hengel-KootFederico VigoritaSeverin VogtWojciech WaldmanWilliam Stephen WaringSergej ZacharovTobias ZellnerDavid M WoodPublished in: Clinical toxicology (Philadelphia, Pa.) (2024)
This study directly compares presentations with acute drug toxicity related to the lone use of cannabis or synthetic cannabinoid receptor agonists. It supports previous findings of increased neuropsychiatric toxicity from synthetic cannabinoid receptor agonists compared to cannabis and provides further data on cardiovascular toxicity in lone cannabis use.